NCT06687174View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 15, 2026

Study Completion Date

January 31, 2028

Conditions
IgA Nephropathy (IgAN)
Interventions
DRUG

MY008211A tablets

MY008211A BID

DRUG

MY008211A tablets matched placebo

Matching placebo to MY008211A taken twice a day.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY